Terminated PHASE3 INTERVENTIONAL 1-arm NCT00197145

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks.

Sponsor: GlaxoSmithKline

Conditions Infection, Human Immunodeficiency Virus I

Interventions GW873140

Updated 10 times since 2017 Last updated: Mar 14, 2018 Started: Jul 21, 2005 Primary completion: Sep 11, 2007 Completion: Sep 11, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from GlaxoSmithKline

See all terminations from GlaxoSmithKline

This PHASE3 trial investigates Infection, Human Immunodeficiency Virus I and is currently terminated or withdrawn. GlaxoSmithKline leads this study, which shows 10 recorded versions since 2005 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 5 earlier versions

Dec 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Dec 2018 [monthly]

Terminated PHASE3
Sep 2017 — Jun 2018 [monthly]

Terminated PHASE3
Feb 2017 — Sep 2017 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
ViiV Healthcare

Data source: ViiV Healthcare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Annandale, United States , Atlanta, United States , Austin, United States , Baltimore, United States , Beverly Hills, United States , Birmingham, United States , Boston, United States , Charlotte, United States , Chicago, United States and 38 more locations